Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia
CLEC12A has recently been identified as an antigen, expressed on leukemic stem cells and leukemic blasts. Given the fact that this expression profile seems stable throughout diagnosis, treatment and relapse on leukemic blasts and leukemic stem cells, CLEC12A can be considered a highly potent and reliable marker for the detection of measurable residual disease and therefore applicable for risk stratification and prognostication in AML. Low CLEC12A expression on leukemic blasts seems to be independently associated with lower likelihood of achieving complete remission after 1  cycle of induction chemotherapy, shorter event free survival, as well as overall survival, indicating potential prognostic properties of CLEC12A expression itself.
Source: Blood Reviews - Category: Hematology Authors: Linde M. Morsink, Roland B. Walter, Gert J. Ossenkoppele Tags: Review Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Hematology | Leukemia | Stem Cell Therapy | Stem Cells